Abstract
The immunoreactivity forbcl-2 oncoprotein was determined in tumor tissue samples from 40 patients with colorectal adenocarcinoma. Positive immunoreactivity forbcl-2 oncoprotein was seen in 14 of the 40 tumor tissue samples (35%) and was found to be associated with a significantly higher incidence of synchronous liver metastasis (P=0.043); however, there was no correlation between the immunoreactivity forbcl-2 oncoprotein and tumor size, depth of tumor invasion, lymph node metastasis, or clinical stage of the disease. Among 33 patients who had undergone curative resection, disease-free survival did not differ significantly between 10 withbcl-2-positive tumors and 23 withbcl-2-negative tumors (P=0.498). The present study showed that the positive immunohistochemical expression ofbcl-2 oncoprotein was associated with a significantly higher incidence of liver metastasis from colorectal cancer, but it had no effect on the disease-free survival of patients who had undergone curative resection.
This is a preview of subscription content, log in via an institution to check access.
References
Korsmeyer SJ (1992)Bcl-2 initiates a new category of oncogenes: regulator of cell death. Blood 80:879–886
Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation. Science 226:1097–1099
Yan J-J, Chen F-F, Tsai Y-C, Jin Y-T (1996) Immunohistochemical detection ofBcl-2 protein in small cell carcinomas Oncology 53:6–11
Astler VB, Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:846–852
Baretton GB, Dieold J, Christoforis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M, Lohrs U (1996) Apoptosis and immunohistochemicalbcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77:255–264
Kaklamanis L, Savage A, Mortensen N, Tsiotos P, Doussis-Anadgnostopolou I, Biddolph S, Whitehouse R, Harris AL, Gatter KC (1996) Early expression ofbcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 179:10–14
Hao XP, Ilyas M, Taibot IC (1997) Expression ofbcl-2 andp53 in the colorectal adenoma-carcinoma sequence. Pathology 65:140–145
Perreira H, Silva S, Juliao R, Garcia P, Perpetua F (1997) Prognostic markers for colorectal cancer: expression ofp53 andbcl-2. World J Surg 21:210–213
Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ, Coggi G, Viale G (1995) Bcl-2 oncoprotein in colorectal hyperplasia polyps, adenomas, and adenocarcinomas. Hum Pathol 26:534–540
Oefner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Toetsch M, Boecker W, Jasani B, Schnid KW (1995) Immunohistochemically detectablebcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 72:981–985
Bhatavdekar JM, Pater DD, Ghosh N, Chikhkilar PR, Trivede TI, Suthar TP, Doctor SS, Sha NG, Balar DB (1977) Coexpression of bcl-2, c-myc, and p53 oncoprotein as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40:785–790
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressorp53 is a regulator ofbcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805
Marin MC, Hsu B, Meyn RE, Donehower LA, El-Naggar AK, Mcdonnell TJ (1994) Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9:3107–3112
Halder S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down regulation ofbcl-2 byp53 in breast cancer cells. Cancer Res 54:2095–2097
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ishijima, N., Miki, C., Ishida, T. et al. The immunohistochemical expression of BCL-2 oncoprotein in colorectal adenocarcinoma. Surg Today 29, 682–684 (1999). https://doi.org/10.1007/BF02483002
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02483002